


INCB3619

## Chemical Properties

CAS No. : 791826-72-7  
 Formula: C<sub>22</sub>H<sub>27</sub>N<sub>3</sub>O<sub>5</sub>  
 Molecular Weight: 413.47  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	INCB3619 is a selective and potent inhibitor of ADAM with antitumour effects, inhibiting ADAM10, ADAM17, MMP12 and MMP15.
Targets(IC50)	Apoptosis,MMP,Immunology/Inflammation related
In vitro	The dual ADAM inhibitor INCB3619 inhibits heregulin cleavage with an IC <sub>50</sub> value of 0.24 μM[1].Treating A549 cells in serum-free culture with varying concentrations of gefitinib and INCB3619 (2-10 μM) for 96 hours revealed that INCB3619 sensitizes A549 cells to gefitinib[1].
In vivo	INCB3619 was administered subcutaneously using ALZET osmotic pumps at doses of 30 or 60 mg/kg/day for 14 days. The results showed that the ADAM inhibitor INCB3619 inhibited gefitinib-resistant HER3 autocrine mechanism, exerting antitumor activity in vivo, and sensitizing tumors to chemotherapy drugs[1].

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4186 mL	12.0928 mL	24.1856 mL
5 mM	0.4837 mL	2.4186 mL	4.8371 mL
10 mM	0.2419 mL	1.2093 mL	2.4186 mL
50 mM	0.0484 mL	0.2419 mL	0.4837 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Bin-Bing S Zhou, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. *Cancer Cell*. 2006 Jul;10(1):39-50.

Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. *Clin Cancer Res*. 2013 Jul 15;19(14):3844-55. doi: 10.1158/1078-0432.CCR-13-0505. PubMed PMID: 23690482; PubMed Central PMCID: PMC3715574.

Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. *Neuro Oncol*. 2012 Oct;14(10):1215-26. PubMed PMID: 22962413; PubMed Central PMCID: PMC3452340.

Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. *Cancer Res*. 2008 Sep 1;68(17):7083-9. doi: 10.1158/0008-5472.CAN-08-0739. PubMed PMID: 18757423.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481